At a glance
CDC works with partners in Nigeria to strengthen the country's public health and clinical systems, deliver quality HIV testing and treatment services, and respond to emerging public health threats.
Background
Established in 2001, CDC's Nigeria office provides technical leadership and assistance to the Ministry of Health and implementing partners. In cooperation, CDC:
- Strategically scales up HIV and tuberculosis (TB) testing, treatment, and prevention.
- Build in-country capacity for high-quality national laboratory services.
- Strengthen epidemiology, disease surveillance, laboratory, blood safety, operations research, and workforce capacity.
Additionally, CDC provides technical guidance to ensure that TB/HIV collaborative activities, as well as TB infection control programs, are strengthened.
Download CDC Nigeria's Fact Sheet
HIV and TB data
HIV/AIDS
Estimated HIV Prevalence (Ages 15-49)
Estimated AIDS Deaths (Age≥15)
Estimated Orphans Due to AIDS
Reported Number Receiving Antiretroviral Therapy (Age≥15)
Tuberculosis (TB)
Estimated TB Incidence
TB Patients with Known HIV-Status who are HIV-Positive
TB Treatment Success Rate
Key activities and accomplishments
Nigeria antiretroviral treatment (ART) surge and retention revolution
CDC supports Nigeria in rapidly identifying people living with HIV (PLHIV). Then, ensuring they are linked to and sustained on treatment, accelerates progress toward achieving HIV epidemic control.
The ART Surge initiative commenced in April 2021 and has changed the treatment landscape in Nigeria. Nearly 2 million PLHIV are on ART as of March 2023, of which 1.2 million are supported by CDC. 16 out of the 18 states and Federal Capital Territory supported by CDC have attained treatment saturation (≥ 81 percent ART coverage).
Additionally, since the implementation of the Retention Revolution Program in 2021, treatment interruptions across CDC-supported states were successfully reduced from 8% in March 2020 to 1 percent by March 2022.
HIV testing services and ART services
CDC supports implementing partners to provide targeted, high-quality, differentiated HIV testing, treatment, and other related services with increasing efficiency.
Between April 2022 and March 2023, CDC, through its partners, provided HIV testing services. CDC reached close to 6.2 million people in Nigeria. 149,244 of them were HIV positive and 145,685 were linked to treatment. In addition, 691,246 orphans and vulnerable children received 1 or more services through CDC implementing partners at the end of March 2023 (PEPFAR Nigeria, 2022).
CDC is implementing a Recent Infection Public Health Response Strategy to improve HIV case finding and reducing HIV transmission. CDC also initiated HIV/TB/COVID-19 integrated services to increase access to care.
Biometric capture for deduplication
CDC works with other U.S. Government agencies as part of a national data quality improvement exercise. The exercises helped the government establish an automated biometric identification system within the National Data Repository (NDR).
By the end of June 2023, the system allowed CDC-supported facilities to collect fingerprints for 1,268,880 (98.4 percent) clients that receive treatment across about 1,200 CDC-supported sites. Fingerprint templates were uploaded to the NDR and linked to client records. Through information exchange, the deduplication of fingerprints was done in an automated biometric information system. The automated biometric system identified about 1,234,646 (97 percent) of the clients' records as unique, while about 34,234 (3 percent) were duplicates.
Prevention of mother-to-child HIV transmission (PMTCT)
CDC worked with local stakeholders and partners to establish 1,044 clinical sites offering PMTCT services. According to the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Nigeria data (April 2021 – March 2022), 1,136,852 pregnant women knew their HIV status at antenatal clinics. Of these, 21,267 women with HIV diagnosis received ART to reduce or prevent mother-to-child transmission. The 27,033 babies born to women with a HIV diagnosis received early infant diagnosis within the first 12 months of life (PEPFAR Nigeria, 2022).
TB and HIV
CDC strengthens integrated TB/HIV activities by providing technical guidance to five implementing partners.
Between April 2022 and March 2023, CDC partners screened 1,202,090 (>97 percent) HIV patients receiving ART for symptoms of TB. Further, 15,721 (100 percent) TB patients knew their HIV status, and 99 percent of those co-infected with HIV started ART. Additionally, 121,215 PLHIV began TB preventive treatment (TPT), and 98 percent completed TPT. This is the highest among all PEPFAR countries, alongside Cote d’Ivoire.
CDC implemented bi-directional screening and testing for TB and COVID-19 for patients and healthcare workers. The efforts support early detection of community-acquired and healthcare-associated TB.
Resources
Support for CDC's global HIV and TB efforts.
Our success is built on the backbone of science and strong partnerships.